“From Hoarding Cash to Spending It”: Berkshire’s Q2 Net Profit Doubles; Abel Deploys $100 Billion in Cash for Acquisitions—What Signal Does This Send?

On August 8, 2026, Berkshire Hathaway delivered a set of financial results that captured market attention. Its net income attributable to shareholders surged 107% year-on-year to $25.667 billion in the second quarter, while operating profit rose steadily by 16%. Yet what stirred investors even more than these headline figures was a fundamental shift in capital allocation by this corporate giant—founded by Warren Buffett and now led by Greg Abel. After 14 consecutive quarters of net stock sales, Berkshire turned to net purchases of nearly $20 billion worth of equities in Q2 and repurchased $4.5 billion of its own shares—the largest such buyback in five years. For the first time, its historically swollen cash reserves began to decline from their peak. This stark transition—“from hoarding cash to spending it”—materialized prominently in Berkshire’s second full quarter under the “post-Buffett era,” signaling far more than just changes in financial metrics. It served both as the first major test of Abel’s capital-allocation philosophy and as a litmus test for whether Berkshire’s investment logic can adapt to the new market environment. I. The End of the “Cash-Hoarding Era”: When “Cash Is King” Gives Way to “Opportunity Cost” Over recent years, Berkshire’s cash holdings climbed to a record $397.4 billion—the largest “war chest” in U.S. corporate history. Buffett’s long-standing, cautious logic was clear: in an overvalued market, holding short-term Treasuries to earn stable returns is far wiser than risking permanent capital loss by chasing inflated valuations. Yet this “stand-still-and-wait” strategy faced dual challenges in 2026. First, performance pressure: As of the end of Q2, Berkshire’s stock had risen only ~3% year-to-date—significantly underperforming the S&P 500, which gained 13% over the same period. The market voted with its feet, expressing dissatisfaction with the inefficient idling of cash. Second, the successor’s mandate: In January 2026, Abel officially succeeded Buffett as CEO. He must prove he is not merely an excellent “steward” preserving Buffett’s legacy, but also a forward-looking “pioneer” for a new era. Berkshire’s massive cash pile is thus both a resource—and a weighty responsibility. Q2 data declared the “cash-hoarding era” over—at least temporarily. As of June 30, Berkshire’s cash and U.S. Treasury holdings stood at approximately $365.5 billion, down more than $30 billion from the prior quarter—the first quarterly sequential decline in four years. This “activated” capital flowed primarily into three directions. II. The Art of Spending: Strategic Intent Behind Three Key Moves 1. Ending 14 Quarters of Net Selling: Aggressive Buying Sends an Offensive Signal The most stunning move in Q2 was Berkshire’s near-$20 billion net equity purchase. Prior to this, the company had recorded net stock sales for 14 straight quarters—even maintaining a net sale pace of roughly $4.5 billion in the first half of 2025. The reversal—from “sell-only” to “aggressively buying”—reflects a major shift in management’s assessment of market opportunities. Berkshire appears to believe that, after a period of correction, valuations of certain high-quality assets have entered reasonable—or even undervalued—territory, warranting large-scale deployment of capital. It also suggests that Abel and his team are engaging in market competition with greater proactivity—not merely waiting for extreme undervaluation.

Behind Ashland’s “Sale”: What Should Chinese Raw Material Companies Understand?

FBeauty Future Track believes that Ancora was able to launch this initiative because Ashland’s assets remain attractive—even though its operational results have failed to satisfy public-market expectations for an extended period. For Chinese cosmetics raw material companies accelerating their entry into capital markets, this contradiction is far more worthy of caution than the acquisition itself. Why Was Ashland Put on the “Trading Block”? Ashland’s current situation can be summed up in one sentence: the company owns strong assets—but has failed to fully translate them into growth visible to shareholders. Founded in the 1920s, Ashland has long operated across high-value-added markets including life sciences, personal care, coatings, and specialty additives. In the beauty sector, its products span cellulose derivatives, film-forming agents, bioactive ingredients, and preservative systems; in pharmaceuticals, many of its offerings require lengthy customer qualification cycles. Such businesses share a defining trait: gaining entry into a customer’s supply chain is difficult—but once achieved, replacement costs are high. In June, Ancora publicly stated that Ashland possesses high-quality end markets, mature customer relationships, and assets protected by significant barriers to entry—yet its stock price had fallen roughly 50% since late 2022. To Ancora, the public-market valuation had already dipped below the potential value of these assets in a control transaction. The root problem lies in execution. From FY2023 to FY2025, Ashland’s sales declined from $2.191 billion to $2.113 billion, then further to $1.824 billion. However, these figures merit closer scrutiny. Of the $289 million revenue decline in FY2025, $153 million stemmed from business divestitures and portfolio optimization; the remainder reflected lower volumes and shifts in pricing mix. In other words, revenue contraction was not solely due to slowing core operations—intentional streamlining was also a key driver. What truly eroded investor patience was the lack of clearly visible growth outcomes following those adjustments. In Q2 of FY2026, Ashland’s sales rose 1% year-on-year—but adjusted EBITDA fell 9%. The company also lowered its full-year guidance, citing slower-than-expected ramp-up at its Hopewell plant, delays in the Calvert City project, and softness in certain end markets. By Q3, conditions improved: sales rose 7% to $497 million, volumes grew 6%, and all four business segments posted revenue gains—yet adjusted EBITDA still declined 4% year-on-year. Clearly, Ashland has not lost orders or technical moats; its life sciences and personal care businesses have even resumed growth. But after years of investment in globalization, innovation, capacity expansion, and portfolio restructuring, capital markets are left wondering: when will these investments finally yield higher profits and stronger cash returns? For shareholders, Ashland’s current value can be realized through two paths: One is continued independent operation—gradually unlocking value via improved efficiency and growth. The other is control-value realization—transferring the entire company to a strategic buyer or private equity firm, enabling new owners to restructure assets, boost efficiency, and reprice the business. Activist investor Ancora clearly favors the latter path.

Ashland Releases Q3 2026 Financial Results

Jul 29, 2026

Ashland Global Holdings reported strong Q3 2026 results, beating expectations with $1.02 EPS and $497 million revenue. Growth was driven by robust demand in its Life Sciences segment, specifically pharmaceutical and nutraceutical applications.

AlphaStreet

2026-07-28

Ashland Inc. Reports Q3 Revenue of $497.0M, Beating Estimates

2026-07-28

Ashland Reports In-Line Q3 Results and Reaffirms Guidance

2026-07-29

Ashland Inc. Posts Q3 Adjusted EPS of $1.02, Exceeding Estimates

2026-07-29

Ashland's Q3 Earnings Miss Estimates, Sales Beat on Volume Growth

2026-07-29

Ashland Releases Q3 2026 Financial Results